Literature DB >> 11082411

Late results of the Warm Heart Trial: the influence of nonfatal cardiac events on late survival.

S E Fremes1, M G Tamariz, D Abramov, G T Christakis, J Y Sever, K Sykora, B S Goldman, C M Feindel, S V Lichtenstein.   

Abstract

BACKGROUND: The Warm Heart Trial randomized 1732 CABG patients to receive warm or cold blood cardioplegia. In the warm cardioplegia patients, nonfatal perioperative cardiac events were significantly decreased and the mortality rate was nonsignificantly decreased (1. 4% versus 2.5%, P:=0.12). The purpose of the present study was to evaluate the late results of these trial patients. METHODS AND
RESULTS: Randomization was stratified according to surgeon and urgency of the operation. Seven hundred sixty-two patients recruited from 1 of the centers were followed through the hospital clinic for late events. Late survival (including perioperative deaths) at 72 months was nonsignificantly greater in the warm cardioplegia patients (94.5+/-1.7%, mean+/-SEM) than in the cold cardioplegia patients (90.9+/-2.6%). Independent predictors of mortality by Cox proportional hazards model were redo CABG, diabetes mellitus, renal insufficiency, and increasing age. The influence of nonfatal perioperative events (perioperative myocardial infarction according to computerized ECG readings or low output syndrome as determined by an outcome committee) on late survival was also analyzed. Late survival at 84 months was significantly reduced in the group who experienced nonfatal perioperative outcomes (94.5+/-1.7% versus 84. 9+/-4.5%, P:<0.001) and remained a significant predictor after adjustment for other important variables (risk ratio 6.4, 95% CI 1. 87 to 8.73, P:<0.0001).
CONCLUSIONS: Effective myocardial protection through either cold or warm blood cardioplegia is essential, because late survival is significantly reduced in patients with nonfatal perioperative cardiac outcomes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11082411     DOI: 10.1161/01.cir.102.suppl_3.iii-339

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  6 in total

Review 1.  Is cold or warm blood cardioplegia superior for myocardial protection?

Authors:  Udo Abah; Patrick Garfjeld Roberts; Muhammad Ishaq; Ravi De Silva
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-03-08

2.  Warm Blood Cardioplegia for Myocardial Protection: Concepts and Controversies.

Authors:  Taylor M James; Marcos Nores; John A Rousou; Nicole Lin; Sotiris C Stamou
Journal:  Tex Heart Inst J       Date:  2020-04-01

3.  Randomized controlled trial of remote ischemic preconditioning and atrial fibrillation in patients undergoing cardiac surgery.

Authors:  Amir S Lotfi; Hossein Eftekhari; Auras R Atreya; Ananth Kashikar; Senthil K Sivalingam; Miguel Giannoni; Paul Visintainer; Daniel Engelman
Journal:  World J Cardiol       Date:  2016-10-26

4.  MicroRNA Expression Profile Changes after Cardiopulmonary Bypass and Ischemia/Reperfusion-Injury in a Porcine Model of Cardioplegic Arrest.

Authors:  Attila Kiss; Stefan Heber; Anne-Margarethe Kramer; Matthias Hackl; Susanna Skalicky; Seth Hallström; Bruno K Podesser; David Santer
Journal:  Diagnostics (Basel)       Date:  2020-04-21

5.  Rationale for Implementation of Warm Cardiac Surgery in Pediatrics.

Authors:  Yves Durandy
Journal:  Front Pediatr       Date:  2016-05-06       Impact factor: 3.418

6.  The effect of perhexiline on myocardial protection during coronary artery surgery: a two-centre, randomized, double-blind, placebo-controlled trial.

Authors:  Nigel E Drury; Neil J Howell; Melanie J Calvert; Ralf J M Weber; Eshan L Senanayake; Michael E Lewis; Jonathan A J Hyde; David H Green; Jorge G Mascaro; Ian C Wilson; Timothy R Graham; Stephen J Rooney; Mark R Viant; Nick Freemantle; Michael P Frenneaux; Domenico Pagano
Journal:  Eur J Cardiothorac Surg       Date:  2014-06-19       Impact factor: 4.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.